4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-22-057968
Chief R&D Officer sold 13,460 shares at $3.57 ($48,052)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan Chief R&D Officer | 2022-11-16 | Sale | −13,460 | $3.57 | $48,052 | 313,663 | D |
| Open-market sales · 13,460 sh · avg $3.57 · $48,052 | |||||||
Loading xslF345X03/doc4.xml…